INTRODUCTION Icatibant, a first-in-class B2 bradykinin receptor antagonist, appears to have a favorable efficacy and safety profile for the treatment of acute attacks of hereditary angioedema in adults. AIMS To update the evidence and provide an overview of the available data on icatibant. EVIDENCE REVIEW Peer reviewed articles published and listed in Medline Search and published updated gu...

BackgroundPhysician surveys on hereditary angioedema (HAE) management in 2010 and 2013 revealed important trends HAE care.ObjectiveTo evaluate current the impact of new treatment options physician practice patterns over time.MethodsDuring June July 2019, 5382 physicians were contacted by means postal mail to complete a 47-question survey; 177 responded (3%).ResultsAcross 3 surveys, home replace...

Management of hereditary angioedema due to C1 inhibitor deficiency has evolved. During the past 10 years, those affected have progressed from underrecognized disability and premature death, through evidence-based hospital treatment, toward self-administration and independence from unscheduled hospital care. Encouraging results from the use of lanadelumab for the prevention of angioedema associa...

Hereditary angioedema (HAE) with C1-inhibitor (C1-Inh) deficiency (C1-Inh-HAE) is a rare, life-threatening, and disabling genetic disorder characterized by self-limited tissue swelling caused by deficiency or dysfunction of C1-Inh. Our aim in this update is to discuss new advances in HAE therapy, focusing mainly on the various treatment options that have become available recently and also drugs...